Skip to content

Net Income at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
-$34.1M-34,000%
Labcorp Holdings logo
Labcorp HoldingsLH
$277.8M+30.5%
Opko Health logo
Opko HealthOPK
-$54.85M+18.9%
NeoGenomics logo
NeoGenomicsNEO
-$17.11M+34.0%
Exagen Inc. logo
Exagen Inc.XGN
-$3.97M-5.7%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$30.03M-90.7%

Other financials

Income statement

See full
Revenue$2.9B+9.2%
Gross profit$942.0M+9.2%
Operating income$399.0M+15.3%
EPS (diluted)$2.24+15.5%

Balance sheet

See full
Cash & equivalents$393.0M+109%
Total debt$6.4B-2.5%
Total equity$7.4B+6.3%
Total assets$16.7B+5.5%

Cash flow

See full
Operating cash flow$278.0M-11.5%
CapEx$114.0M-2.6%
Free cash flow$164.0M-16.8%

Valuation

See full
Market cap$23.46B+20.8%
Enterprise value$29.48B+15.7%
P/E22.9×+2.5×
P/S2.1×+0.2×

Profitability

See full
Gross margin33.2%+0.4pp
Operating margin14.3%+0.6pp
Net margin9.1%+0.2pp
FCF margin11.8%+1.4pp

Returns & leverage

See full
Return on equity14.3%+0.9pp
Debt / equity0.9×-0.1×
Current ratio1.2×-0.3×

Where this comes from

Reported directly by Quest Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Quest Diagnostics’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Quest Diagnostics's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Quest Diagnostics's net income?
Quest Diagnostics (DGX) reported net income of $252M in Q1 2026.
How has Quest Diagnostics's net income changed year-over-year?
Quest Diagnostics's net income increased by 14.5% year-over-year, from $220M to $252M.
What is the long-term trend for Quest Diagnostics's net income?
Over 4 years (2021 to 2025), Quest Diagnostics's net income has grown at a -16.0% compound annual growth rate (CAGR), from $2B to $992M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.